Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors
Open Access
- 27 October 2023
- journal article
- research article
- Published by Elsevier in JACC: Advances
- Vol. 2 (9) , 100669
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II StudyJournal of the American Heart Association, 2016
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized TrialThe Journal of Clinical Endocrinology & Metabolism, 2015
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I studyAmerican Heart Journal, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsThe Lancet, 2015
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trialEuropean Heart Journal, 2015
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trialInternational Journal of Cardiology, 2014
- Anti-PCSK9 Monotherapy for HypercholesterolemiaJACC, 2014
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet, 2012